company background image
CTXR

Citius Pharmaceuticals NasdaqCM:CTXR Stock Report

Last Price

US$1.16

Market Cap

US$169.5m

7D

0%

1Y

-28.4%

Updated

28 Nov, 2022

Data

Company Financials +
CTXR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CTXR Stock Overview

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy.

Citius Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Citius Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.16
52 Week HighUS$2.01
52 Week LowUS$0.83
Beta1.16
1 Month Change3.57%
3 Month Change-3.33%
1 Year Change-28.40%
3 Year Change163.64%
5 Year Change-75.88%
Change since IPO-92.27%

Recent News & Updates

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05
Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Recent updates

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05
Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28
Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

May 15
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Dec 18
Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Shareholder Returns

CTXRUS PharmaceuticalsUS Market
7D0%1.5%0.3%
1Y-28.4%12.2%-20.5%

Return vs Industry: CTXR underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: CTXR underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is CTXR's price volatile compared to industry and market?
CTXR volatility
CTXR Average Weekly Movement6.7%
Pharmaceuticals Industry Average Movement10.8%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: CTXR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CTXR's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200715Leonard Mazurhttps://www.citiuspharma.com

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals, Inc. Fundamentals Summary

How do Citius Pharmaceuticals's earnings and revenue compare to its market cap?
CTXR fundamental statistics
Market CapUS$169.51m
Earnings (TTM)-US$30.61m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CTXR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$30.61m
Earnings-US$30.61m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.21
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CTXR perform over the long term?

See historical performance and comparison